Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Crump

Showing results (71-80 of 183) with videos related to

Pageof 19
Sort By:
British Journal of Haematology|October 27, 2023
Indolent lymphoma care delivery and outcomes during the COVID-19 pandemic in Ontario, CanadaInna Y Gong, Anca Prica, Zharmaine Ante, et al.
Haematologica|May 13, 2010
Different response to salvage chemotherapy but similar post-transplant outcomes in patients with relapsed and refractory Hodgkin's lymphomaNoemi Puig, Melania Pintilie, Tara Seshadri, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 8, 2016
Phase I Study of Inotuzumab Ozogamicin Combined with R-CVP for Relapsed/Refractory CD22+ B-cell Non-Hodgkin LymphomaMichinori Ogura, Kensei Tobinai, Kiyohiko Hatake, et al.
Haematologica|November 4, 2017
A bioclinical prognostic model using MYC and BCL2 predicts outcome in relapsed/refractory diffuse large B-cell lymphomaMark Bosch, Ariz Akhter, Bingshu E Chen, et al.
Cancer Cytopathology|March 27, 2015
Multiplex sequencing for EZH2, CD79B, and MYD88 mutations using archival cytospin preparations from B-cell non-Hodgkin lymphoma aspirates previously tested for MYC rearrangement and IGH/BCL2 translocationGilda da Cunha Santos, Mauro Ajaj Saieg, Hyang Mi Ko, et al.
Blood Neoplasia|August 4, 2025
Outcomes and factors influencing survival in patients with diffuse large B-cell lymphoma: a population-based analysisInna Y Gong, Michael Crump, Anca Prica, et al.
The Oncologist|May 25, 2023
Contact Days Associated With Cancer Treatments in the CCTG LY.12 TrialArjun Gupta, Annette E Hay, Michael Crump, et al.
Blood|March 23, 2012
A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignanciesLaurie H Sehn, Sarit E Assouline, Douglas A Stewart, et al.
Leukemia & Lymphoma|July 17, 2012
Limited-stage mantle cell lymphoma: treatment outcomes at the Princess Margaret HospitalMaryse Bernard, Richard W Tsang, Lisa W Le, et al.
International Journal of Radiation Oncology, Biology, Physics|June 8, 2012
Role of salvage radiation therapy for patients with relapsed or refractory hodgkin lymphoma who failed autologous stem cell transplantJayant S Goda, Christine Massey, John Kuruvilla, et al.
Pageof 19

Showing results (71-80 of 183) with videos related to

Sort By:
Pageof 19
British Journal of Haematology|October 27, 2023
Indolent lymphoma care delivery and outcomes during the COVID-19 pandemic in Ontario, CanadaInna Y Gong, Anca Prica, Zharmaine Ante, et al.
Haematologica|May 13, 2010
Different response to salvage chemotherapy but similar post-transplant outcomes in patients with relapsed and refractory Hodgkin's lymphomaNoemi Puig, Melania Pintilie, Tara Seshadri, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 8, 2016
Phase I Study of Inotuzumab Ozogamicin Combined with R-CVP for Relapsed/Refractory CD22+ B-cell Non-Hodgkin LymphomaMichinori Ogura, Kensei Tobinai, Kiyohiko Hatake, et al.
Haematologica|November 4, 2017
A bioclinical prognostic model using MYC and BCL2 predicts outcome in relapsed/refractory diffuse large B-cell lymphomaMark Bosch, Ariz Akhter, Bingshu E Chen, et al.
Cancer Cytopathology|March 27, 2015
Multiplex sequencing for EZH2, CD79B, and MYD88 mutations using archival cytospin preparations from B-cell non-Hodgkin lymphoma aspirates previously tested for MYC rearrangement and IGH/BCL2 translocationGilda da Cunha Santos, Mauro Ajaj Saieg, Hyang Mi Ko, et al.
Blood Neoplasia|August 4, 2025
Outcomes and factors influencing survival in patients with diffuse large B-cell lymphoma: a population-based analysisInna Y Gong, Michael Crump, Anca Prica, et al.
The Oncologist|May 25, 2023
Contact Days Associated With Cancer Treatments in the CCTG LY.12 TrialArjun Gupta, Annette E Hay, Michael Crump, et al.
Blood|March 23, 2012
A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignanciesLaurie H Sehn, Sarit E Assouline, Douglas A Stewart, et al.
Leukemia & Lymphoma|July 17, 2012
Limited-stage mantle cell lymphoma: treatment outcomes at the Princess Margaret HospitalMaryse Bernard, Richard W Tsang, Lisa W Le, et al.
International Journal of Radiation Oncology, Biology, Physics|June 8, 2012
Role of salvage radiation therapy for patients with relapsed or refractory hodgkin lymphoma who failed autologous stem cell transplantJayant S Goda, Christine Massey, John Kuruvilla, et al.
Pageof 19